SCOPUS 정보 검색 플랫폼

Multiple Sclerosis

Volumn 9, Issue 6, 2003, Pages 627-629

Towards a European Network for Multiple Sclerosis Trials (ENMST)

(8) Kappos, Ludwig a Polman, C b Thompson, A J c Duda, P a Clanet, M d Comi, G e Hartung, H P f Montalban, X g

a UNIVERSITY HOSPITAL BASEL (Switzerland)

b VU UNIVERSITY AMSTERDAM (Netherlands)

c National Hospital (United Kingdom)

d CHU PURPAN (France)

e SAN RAFFAELE HOSPITAL (Italy)

f HEINRICH HEINE UNIVERSITY (Germany)

g University Hospital (Spain)

Author keywords

Clinical trials; Methods; Multiple sclerosis; Quality standards

Indexed keywords

PLACEBO;

CLINICAL PROTOCOL; CLINICAL RESEARCH; COMPARATIVE STUDY; DRUG INDUSTRY; EUROPE; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HEALTH CARE FINANCING; HEALTH CARE ORGANIZATION; HUMAN; MULTIPLE SCLEROSIS; OUTCOMES RESEARCH; QUALITY CONTROL; REVIEW; SOCIOECONOMICS; STANDARD; STATISTICAL SIGNIFICANCE; TREATMENT PLANNING;

CLINICAL TRIALS; EUROPE; HUMANS; INTERNATIONAL COOPERATION; MULTIPLE SCLEROSIS; PRACTICE GUIDELINES;

EID: 0344961114 PISSN: 13524585 EISSN: None Source Type: Journal
DOI: 10.1191/1352458503ms962xx Document Type: Review

Times cited : (3)

References (17)

1
- 0029279166
- Outcomes assessment in multiple sclerosis clinical trials: A critical analysis
- Whitaker JN, McFarland HF, Rudge P, Reingold SC. Outcomes assessment in multiple sclerosis clinical trials: A critical analysis. Mult Scler 1995; 1: 37-47.
- (1995) Mult Scler , vol.1 , pp. 37-47
- Whitaker, J.N.¹ McFarland, H.F.² Rudge, P.³ Reingold, S.C.⁴

2
- 0344942334
- CPMP/ICH/135/95; adopted January 1997
- ICH E6 Consolidated Guideline on Good Clinical Practice. CPMP/ICH/135/95; adopted January 1997.
- ICH E6 Consolidated Guideline on Good Clinical Practice

3
- 0034682156
- Uneasy alliance. Clinical investigators and the pharmaceutical industry
- Bodenheimer T. Uneasy alliance. Clinical investigators and the pharmaceutical industry. N Engl J Med 2000; 342: 1539-44.
- (2000) N Engl J Med , vol.342 , pp. 1539-1544
- Bodenheimer, T.¹

4
- 0343415162
- Academia and industry: Increasingly uneasy bedfellows
- Weatherall D. Academia and industry: Increasingly uneasy bedfellows. Lancet 2000; 355: 1574.
- (2000) Lancet , vol.355 , pp. 1574
- Weatherall, D.¹

5
- 0037180455
- When marketing and science intersect: Do patients with MS benefit?
- Lublin F. When marketing and science intersect: Do patients with MS benefit? Neurology 2002; 59: 1480-81.
- (2002) Neurology , vol.59 , pp. 1480-1481
- Lublin, F.¹

6
- 0033608864
- Are clinical trials of therapeutic agents for MS long enough?
- Rudge P. Are clinical trials of therapeutic agents for MS long enough? Lancet 1999; 353: 1033-34.
- (1999) Lancet , vol.353 , pp. 1033-1034
- Rudge, P.¹

7
- 85046519408
- Multiple sclerosis trials
- Kappos L. Multiple sclerosis trials. Lancet 1999; 353: 2242-43.
- (1999) Lancet , vol.353 , pp. 2242-2243
- Kappos, L.¹

8
- 0035909094
- Autorship, sponsorship, and accountability
- Davidoff F, DeAngelis CD, Drazen JM, Hoey J, Hojgaard L, Horton R et al. Autorship, sponsorship, and accountability. Ann Intern Med 2001; 135: 463-66.
- (2001) Ann Intern Med , vol.135 , pp. 463-466
- Davidoff, F.¹ DeAngelis, C.D.² Drazen, J.M.³ Hoey, J.⁴ Hojgaard, L.⁵ Horton, R.⁶

9
- 0034814994
- Also published in: CMAJ 2001; 165: 786-88;
- (2001) CMAJ , vol.165 , pp. 786-788
- Davidoff, F.¹ DeAngelis, C.D.² Drazen, J.M.³ Hoey, J.⁴ Hojgaard, L.⁵ Horton, R.⁶

10
- 0035850417
- JAMA 2001; 286: 1232-34;
- (2001) JAMA , vol.286 , pp. 1232
- Davidoff, E.¹ DeAngelis, C.D.² Drazen, J.M.³ Hoey, J.⁴ Hojgaard, L.⁵ Horton, R.⁶

11
- 0035883995
- Lancet 2001; 358: 854-56;
- (2001) Lancet , vol.358 , pp. 854-856
- Davidoff, F.¹ DeAngelis, C.D.² Drazen, J.M.³ Hoey, J.⁴ Hojgaard, L.⁵ Horton, R.⁶

12
- 0035856026
- N Engl J Med 2001; 345: 825-27.
- (2001) N Engl J Med , vol.345 , pp. 825-827
- Davidoff, F.¹ DeAngelis, C.D.² Drazen, J.M.³ Hoey, J.⁴ Hojgaard, L.⁵ Horton, R.⁶

13
- 0029913882
- Defining the clinical course of multiple sclerosis: Results of an international survey
- Lublin F, Reingold SC. Defining the clinical course of multiple sclerosis: Results of an international survey. Neurology 1996; 46: 907-11.
- (1996) Neurology , vol.46 , pp. 907-911
- Lublin, F.¹ Reingold, S.C.²

14
- 0034101317
- Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: Effects of heterogeneity of disease course in placebo cohorts
- Liu C, Blumhardt LD. Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: Effects of heterogeneity of disease course in placebo cohorts. J Neurol Neurosurg Psychiatry 2000; 68: 450-57.
- (2000) J Neurol Neurosurg Psychiatry , vol.68 , pp. 450-457
- Liu, C.¹ Blumhardt, L.D.²

15
- 0345373670
- Accessed August 2003
- http://www.SLCMSR.org. Accessed August 2003.

16
- 0035003051
- Placebo-controlled clinical trials in multiple sclerosis: Ethical considerations. National Sclerosis Society (USA). Task force on placebo-controlled clinical trials in MS
- Lublin F, Reingold SC. Placebo-controlled clinical trials in multiple sclerosis: Ethical considerations. National Sclerosis Society (USA). Task force on placebo-controlled clinical trials in MS. Ann Neurol 2001; 49: 677-81.
- (2001) Ann Neurol , vol.49 , pp. 677-681
- Lublin, F.¹ Reingold, S.C.²

17
- 0023185342
- Equipoise and the ethics of clinical research
- Freedman B. Equipoise and the ethics of clinical research. N Engl J Med 1987; 317: 141-45.
- (1987) N Engl J Med , vol.317 , pp. 141-145
- Freedman, B.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.